FilingReader Intelligence

Stemrim reports interim loss, cites R&D investment, pipeline progress

March 27, 2025 at 07:39 PM UTC•By FilingReader AI

Stemrim (TSE:4599) reported its financial results for the second quarter of the fiscal year ending July 2025, showing an operating loss of ¥1,066 million and a net loss of ¥1,048 million. The losses reflect the company’s continued investment in research and development, particularly for its regenerative-inducing medicine pipeline.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Summary of financial results for the second quarter (interim period) of the fiscal year ending July 2025 [Japanese GAAP] (non-consolidated)March 12, 2025 at 06:30 AM UTC

Supplementary Source Documents

Non-consolidated Financial Results for the Six Months Ended January 31, 2025 [Japanese GAAP]March 12, 2025 at 06:37 AM UTC

Stemrim

TSE:4599•Tokyo Stock Exchange

RSS feed for Stemrim

News Alerts

Get instant email alerts when Stemrim publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →